by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
Australian Journal of Pharmacy : March 2005
ical outcome measures, (for example blood glucose, total cholesterol, INR, monitoring blood pressure, body weight and body mass index). • The pharmacist could also remind patients of the importance of regular reviews for side-effect monitoring (for example serum electrolytes and creati- nine, amiodarone toxicity such as thy- roid function tests, heart rate and rhythm assessments and the presence of diabetic complications, for example, eye and feet examinations).71 • Ensuring the quality and evidence- based use of medications including use of lipid-lowering drugs, aspirin, beta- blockers and ACE inhibitors when appropriate. • Collaborative drug therapy manage- ment by pharmacists working in the context of a pre-defined protocol enable selected prescribing, monitoring and dose adjusting strategies.72,73 • Using evidence-based recommenda- tions and screening tools, the pharma- cist can identify individuals at high risk of thromboembolism and assist in the selection of appropriate prophylactic antithrombotic therapy and provision of continuity of care. • The development of informatics has already and will continue to change the management of patients in primary healthcare, thus expanding the future role of community pharmacists. Summary Various strategies used to reduce burden of CVD have included implementation of health promotion units, development of cardiac rehabilitation programs sup- ported by nursing and allied health pro- fessionals, use of multidisciplinary teams in home-based programs, and develop- ment of specialist clinics and home-based programs. These programs have not always involved pharmacists. It is clear that there is significant poten- tial for pharmacists to contribute to opti- mal treatment of CVD by taking an active role in DSM programs and thereby sup- porting consumers and other health prac- titioners, particularly the GP. ¦ THE AUSTRALIAN JOURNAL OF PHARMACY VOL.86 MARCH 2005 ? 169 CPE POINTS Articles in Pharmacy Practice Foundation Research offer readers who are members of the Australian College of Pharmacy Practice and Management the opportunity to take the following test and gain half (0.5) a CPE credit point. Answers should be submitted by the 25th of the month following the month of issue. Mark the correct statements.There is only one correct statement per question. Answers with your name and address should be forwarded to: ACPP, PO BOX 7007, CANBERRA BC ACT 2610 or fax: (02) 6273 8988 or submit postage-free online through the Online CPE tab on the ACPP website: http://www.acpp.edu.au (Choose ‘Australian Journal of Pharmacy’) 1. Two risk factors for cardiovascular disease are: (a) tobacco smoking and low alcohol intake. (b) high cholesterol levels and hypotension. (c) hypertension and physical inactivity. (d) diabetes and low cholesterol levels. 2. Issues regarding the epidemiology of cardiovascular disease include: (a) A quarter of the population with impaired glucose tolerance or diabetes have not been diagnosed. (b) The prevalence of heart failure is decreasing. (c) Atrial fibrillation affects >10 per cent of the population over 35 years of age. (d) There are on average at least 100 heart failure patients per pharmacy. 3. Consultations with consumers regarding medications have found that: (a) consumers don’t mind how much medications cost. (b) consumers want doctors to completely manage their care. (c) consumers only want complementary and alternative medication advice from their pharmacists. (d) consumers wish for timely and independent advice. 4. Issues related to poor medication use in cardiovascular diseases include: (a) low uptake of diuretics in heart failure. (b) poor long term adherence rates with statins. (c) poor cardiologists’ knowledge regarding role of medications. (d) high warfarin use in atrial fibrillation. 5. Roles for community pharmacists in the management of cardiovascular conditions could include: (a) performing echocardiographs. (b) monitoring patient adherence to medications and lifestyle measures. (c) performing venepuncture. (d) diagnosing heart failure.